Fangzhou completed its global offering and listing on The Stock Exchange of Hong Kong Limited with a market capitalization of $1.4 billion.
Fangzhou is the largest online chronic disease management platform in China in terms of average monthly active users, as of 2023. Fangzhou provides follow-up physician consultations, e-prescription and online retail pharmacy services through its hospital-to-home service platform.
S&C acted for the underwriters, led by Citigroup and ABCI, on both Hong Kong and U.S. law matters.
The S&C team was led by Kay Ian Ng and Ching-Yang Lin in Hong Kong and Gwen Wong in Beijing and included Dickson Wong, Yiwen Wang and Steve Lee. Jeff Hochberg and Tristan Hood advised on U.S. tax matters.